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Abstract
Background: Statins have immunomodulatory properties and hinder Candida growth. However, it is unknown
whether they may improve prognosis in patients with candidemia. We sought to determine the effect of prior statin
use on the clinical outcomes of patients suffering candidemia.
Methods and Findings: Multicenter cohort study of hospitalized adults with candidemia between 2005 and 2011 in
six hospitals in Spain, Brazil and Argentina. Of 326 candidemias, 44 (13.5%) occurred in statin users and 282
(86.5%) in statin non-users. The median value of APACHE II at candidemia diagnosis was similar between groups
(18 vs. 16; p=.36). Candida albicans was the most commonly isolated species, followed by C. parapsilosis, C.
tropicalis, C. glabrata, and C. krusei. There were no differences regarding appropriate empirical antifungal treatment.
Statin users had a lower early (5 d) case-fatality rate than non-users (4.5 vs. 17%; p=.031). This effect was not
observed with other cardiovascular drugs (aspirin, beta blockers and ACE inhibitors). Independent factor related to
early case-fatality rate was APACHE II score (AOR, 1.08; 95% CI, 1.03–1.14; p=.002). An appropriate empirical
antifungal therapy (AOR, 0.11; 95% CI, 0.04–0.26; p=<.001) and prior statin use were independently associated with
lower early case-fatality (AOR, 0.17; 95% CI, 0.03–0.93; p=.041). Fourteen days (14d) and overall (30d) case-fatality
rates were similar between groups (27% vs. 29%; p=0.77 and 40% vs. 44%; p=.66).
Conclusions: The use of statins might have a beneficial effect on outcomes of patients with candidemia. This
hypothesis deserves further evaluation in randomized trials.
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Introduction
Candidemia is a common cause of nosocomial bloodstream
infections worldwide [1,2] and is associated with significant
morbidity, prolonged hospital stay, high mortality and increased
health care costs [3]. Importantly, some investigators report
that overall mortality has not decreased over the past decades
[1-4].
Hydroxymethylglutaryl-CoA reductase inhibitors, also known
as statins, are increasingly used in clinical practice to treat
dyslipidemia. Statin therapy has been shown to decrease
cardiovascular events and mortality from coronary artery
disease [5]. Interestingly, statins exhibit potent anti-
inflammatory, anticoagulant, and anti-oxidative effects called
“pleiotropic properties” [6]. Due to these properties, it has been
suggested that these drugs may have beneficial effects during
sepsis. Experimental and observational studies [7,8] have
shown that statin therapy reduces inflammatory cytokines [9].
There is an increasing interest in determining whether statins
improve prognosis of patients with severe infections. The
results of certain observational studies suggest that statins may
reduce mortality in patients suffering from sepsis [8,10,11],
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bacteremia [12], community-acquired bacterial pneumonia
[7,13,14] and even influenza [15,16]. On the other hand, in vitro
studies have found that statins have an intrinsic antifungal
effect, hindering fungal growth [17].
However, information evaluating the effects of statin therapy
on clinical outcomes of patients with candidemia is scarce. The
purpose of this study is to assess whether prior statin use is
associated with a decreased risk of mortality in a large
multicenter cohort of adult patients with candidemia.
Methods
Setting, patients, and study design
We performed a retrospective multicenter study of all
episodes of candidemia occurring in hospitalized adult patients
between January 2005 and December 2011 at six tertiary
teaching institutions in three different countries: three in Spain,
two in Argentina and one in Brazil. Only the first episode of
candidemia for each patient was analyzed. The following
information was carefully collected from medical records:
demographic characteristics, comorbidities, statin use and
other concurrent cardiovascular medications (aspirin, beta
blockers and angiotensin II-converting enzyme inhibitors),
clinical features, sources of candidemia, causative species,
antifungal therapy and outcomes. Episodes of candidemia
occurring in statin users were compared with those occurring in
statin non-users. To protect personal privacy, identifying
information of each patient in the electronic database was
encrypted. Informed consent was waived by the Clinical
Research Ethics Committee because no intervention was
involved and no patient identifying information was included.
Definitions
Candidemia and catheter-related candidemia were defined
on the basis of the guidelines of the Infectious Diseases
Society of America [1]. Secondary candidemia was defined as
a documented concurrent infection caused by the same
Candida species at a site other than the catheter [18]. An
episode of candidemia was considered to be nosocomially
acquired, community-acquired or healthcare-associated as
described elsewhere [19]. Statin use was considered to be
present in those patients who were taking a statin (simvastatin,
atorvastatin, lovastatin, pravastatin or rosuvastatin) within the 7
days prior to the candidemia episode. Seven days period was
used due to pleitropic effects of statins may persist despite
temporary cessation of administration. The use of other
cardiovascular drugs like aspirin, beta-blockers and
angiotensin II-converting enzyme (ACE) inhibitors was
considered to be present in patients who were taking these
drugs within the 30 days prior to the candidemia episode. The
diagnosis of septic shock was based on a systolic blood
pressure of less than 90 mm Hg and peripheral hypoperfusion
with the need for vasopressors [20]. Neutropenia was
considered when the granulocyte count was <500/ mm3.
Empirical antifungal therapy was considered to be appropriate
when the Candida isolates showed in vitro susceptibility to the
antifungal drug administered. When antifungal susceptibility
testing was not available, we considered fluconazole,
amphotericin B or an equinocandin as appropriate empirical
antifungal treatment for Candida albicans, Candida tropicalis,
Candida parapsilosis and Candida lusitaniae. For Candida
glabrata and Candida krusei, empirical antifungal treatment
was considered to be appropriate when an equinocandin or
amphotericin B was administered. The early, 14 days and
overall case-fatality rates were defined as death from any
cause within five, fourteen and 30 days after the onset of
candidemia respectively.
Microbiological studies
Two sets of two blood samples were drawn from patients
with suspected bloodstream infection. Blood samples were
processed by the BACTEC 9240 system (Becton Dickinson
Microbiology Systems, Franklin Lakes, NJ, USA) with an
incubation period of five days. If yeast cells were observed
after microscopic examination of Gram stain, blood bottles
were subcultured onto Sabouraud agar plates (BD BBL
StrackerTM PlatesTM, Heidelberg, Germany) and chromogenic
media (CAN2 ChromID™Candida Agar, BioMerieux, Paris,
France). Yeast isolates were identified by conventional
methods. In vitro antifungal activity was studied by a
commercial microdilution method (YeastOne®Sensitre®, TREK
Diagnostic Systems Ltd, England) or by E-test (BioMerieux SA,
Paris, France), in accordance with the manufacturer’s
instructions. Antifungal susceptibility of isolates was classified
according to the Clinical and Laboratory Standards Institute
M27-A3 document [21].
Statistical analysis
The results were analyzed using SPSS version 15.0 (SPSS
Inc., Chicago, IL, USA). To detect significant differences
between groups, we used the Chi-square test or Fisher’s exact
test for categorical variables and the Student t-test or Mann-
Whitney test for continuous variables, as appropriate. We
performed a multivariate logistic regression analysis of factors
potentially associated with mortality included all variables that
were significant in the univariate analysis. Due to the baseline
imbalances between patients, a propensity score for receiving
statin therapy was added to the model. The propensity score
(PS), probability of receiving statins, was calculated using
multivariate logistic regression model and included the
following variables: age, Charlson index, place of acquisition
(inpatient or outpatient, with the first as a reference),
neutropenia and urinary catheter. The model showed a P value
of 0,646 for the Hosmer-Lemeshow test and an area under
curve of 0.73, showing good predictive ability. The relative risks
were expressed as adjusted odds ratios (AOR) and 95%
confidence intervals. Goodness-of-fit of the final model was
assessed by the Hosmer-Lemeshow test. Statistical
significance was established at α=0.05. All reported p-values
are two-tailed.
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Results
Patient characteristics
Over the study period we documented 326 candidemias, 44
(13.5%) occurring in statin users and 282 (86.5%) in statin non-
users. The epidemiological and clinical characteristics of the
patients are outlined in Table 1. Comparing with statin non-
users, statin users were older and more frequently had chronic
renal disease, diabetes mellitus and chronic heart disease. The
presence of a urinary catheter was also more frequent in this
group. Conversely, statin users had less chronic liver disease
and neutropenia. The median value of APACHE II at
candidemia diagnosis was similar in the two groups.
Candida species
Among the species, the most frequent was Candida albicans
followed by C. parapsilosis, C. tropicalis, C. glabrata, and C.
krusei without significant differences between statin users and
statin non-users. The place of acquisition, the likely source of
infection and the species isolated are detailed in Table 2.
Treatment and outcomes
The treatment and clinical outcomes are detailed in Table 3.
More than 70% of patients received an appropriate empirical
antifungal treatment without significant differences between
groups. The most frequently used drug was fluconazole,
followed by anidulafungin. No significant differences were
found in catheter removal between groups. No differences
were observed in persistent candidemia, instability after 48
hours of treatment or septic metastases. The early case fatality
rate was lower among statin users (n=2: 4.5% vs. n=48: 17%;
p=.031). After adjusting for Propensity Score, the statins also
decrease the probability of early case-fatality rate significantly
(p = 0.014). This effect was not observed with any of the other
cardiovascular drugs analyzed, including aspirin (odds ratio
[OR], 1.5; 95% confidence interval [CI], 0.65–3.5; p=0.34), beta
blockers (OR, 0.69; 95% CI, 0.23–2.0; p=0.49) or with ACE
inhibitors (OR, 0.69; 95% CI, 0.3–1.5; p=0.36). Fourteen days
(14d) and overall (30d) case-fatality rates were similar between
groups (27% vs. 29%; p=0.77 and 40% vs. 44%; p=.66,
respectively). The results were equivalent when neutropenic
patients were excluded.
Independent factors associated with early case-fatality
rate
Multivariate analysis adjusted for risk factors associated with
mortality and including the propensity score is described in
Table 4. The APACHE II score was an independent factors
related to mortality (AOR, 1.08; 95% CI, 1.03-1.14; p=.002). An
appropriate empirical antifungal therapy (AOR, 0.11; 95% CI,
0.04-0.26; p=<.001) and prior statin use were independently
associated with lower early case-fatality (AOR, 0.17; 95% CI,
0.03–0.93; p=.041).
Discussion
In this multicenter study involving a large number of
hospitalized adults with candidemia, we found that patients
who had received statins had lower early case-fatality rate
compared with those who were not receiving statins.
Interestingly, the survival benefit observed persisted after
adjustment for confounders by multivariate analysis.
To date, candidemia remains to be associated with
significant morbidity and mortality. In the present study, the
overall case-fatality rate exceeded 40%, similar to those
Table 1. Clinical characteristics of patients by statin group.
 
Statin users
(n=44) No. (%)
Statin non-users
(n=282) No. (%) p-value
Demographics    
Male sex 24 (54.5) 165 (58.5) .620
Age, median (IQR) years 64 (56-74) 57 (43-70) .006
Comorbid conditions    
Chronic renal disease 18 (40.9) 63 (22.3) .008
Dialysis 6 (13.6) 17 (6) .067
Diabetes mellitus 22 (50) 67 (23.8) <.001
COPD 10 (22.7) 57 (20.2) .710
Chronic heart disease 25 (56.8) 61 (21.6) <.001
Cerebrovascular disease 8 (18.2) 40 (14.2) .505
Liver disease 2 (4.5) 52 (18.4) .021
Malignancy 16 (36.4) 111 (39.4) .692
Stem cell transplantation 2 (4.5) 20 (7.1) .394
Graft versus Host disease 0 (0) 8 (2.8) .273
Solid organ transplantation 6 (13.6) 26 (9.2) .364
HIV infection 0 (0) 14 (5) .131
Risk factors    
ICU stay 20 (45.5) 132 (46.8) .802
Mechanical ventilation 18 (40.9) 103 (36.5) .636
Total parenteral nutrition 13 (29.5) 88 (31.2) .768
Vasopressor therapy 10 (22.7) 78 (27.7) .430
Previous surgery 23 (52.3) 112 (39.7) .120
Catheter placement (>48h) 41 (93.2) 248 (87.9) .360
Urinary catheter 32 (72.7) 130 (46.1) .002
Neutropenia 0 (0) 42 (14.9) .006
Chemotherapy 4 (9.1) 58 (20.6) .070
Radiotherapy 1 (2.3) 9 (3.2) .735
Corticosteroid therapy 15 (34.1) 133 (47.2) .122
Prior antibiotic therapy 41 (93.2) 256 (90.8) .801
Immunosuppressive therapy 10 (22.7) 65 (23) .953
Antifungal prophylaxis 2 (4.5) 35 (12.4) .120
Clinical characteristics (at
candidemia diagnosis)    
Fever 38 (86.4) 213 (75.5) .169
Hypotension 26 (59.1) 125 (44.3) .293
Vasopressor therapy
requirement 16 (36.4) 83 (29.4) .402
Acute renal failure 18 (40.9) 81 (28.7) .127
Confusion 20 (45.5) 98 (34.8) .217
APACHE II, median (IQR) 18 (11-23) 16 (11-23) .365
doi: 10.1371/journal.pone.0077317.t001
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reported in most series [3,22–26]. The early case-fatality rate
was 4.5%. This figure is difficult to compare with others
obtained in previous series because little information is
available regarding frequency and associated factors. We
found that APACHE II score was an independent factors
related to mortality whereas an appropriate empirical antifungal
therapy and prior statin use were independently associated
with lower early case-fatality.
Statins were also associated with a lower overall (30d) case-
fatality rate in ICU patients with candidemia in a previous
single-center study conducted by Forrest et al [27]. That study
had a small sample size (45 patients, including 15 statin users)
and the exposure groups presented significant differences in
APACHE II score. However, the overall survival benefit was not
statistically significant when adjusted for APACHE II score.
Another recent single-center study [28] did not show any
benefit in the outcomes of patient with candidemia receiving
statins. It was a small study (14 statin users) and did not
evaluate the differences in the severity of the disease between
groups. None of these studies analyzed the effect of statins in
early mortality.
It might be speculated that the lower early case-fatality rates
observed in statin users are due to the pleiotropic effects of
statins. There is substantial evidence from basic science of the
immunonodulatory role of statins in patients with sepsis, who
present reductions in proinflammatory cytokines (TNF-α and
IL-6) [9], induction of haem oxygenase, direct alteration of
Table 2. Sources of candidemia and Candida species
according to statin groups.
 
Statin users (n=44)
No. (%)
Statin non-users
(n=282) No. (%) p-value
Site of acquisition *   .018
Nosocomially-acquired 37 (84.1) 242 (85.8)  
Community-acquired 7 (15.9) 15 (5.3)  
Healthcare-associated 0 (0) 23 (8.2)  
Source of infection   .615
Urinary tract 8 (18.2) 29 (10.3)  
Digestive tract and
abdomen 4 (9.1) 44 (15.6)  
Catheter related infection 9 (20.5) 64 (22.7)  
Skin and soft tissue 1 (2.3) 3 (1.1)  
Surgical site infection 1 (2.3) 3 (1.1)  
Endocarditis 0 (0) 3 (1.1)  
Unknown 21 (47.7) 134 (47.5)  
Others 0 (0) 2 (0.7)  
Candida species    
C. albicans 21 (47.7) 121 (42.9) .549
C. parapsilosis 13 (29.5) 53 (18.8) .099
C. glabrata 3 (6.8) 32 (11.3) .367
C. tropicalis 6 (13.6) 41 (14.5) .874
C. krusei 1 (2.3) 11 (3.9) .594
C. lusitaniae 0 (0) 2 (0.7) .575
Others 0 (0) 22 (7.8) .055
*. The site of acquisition was not known in 2 patients.
doi: 10.1371/journal.pone.0077317.t002
leucocyte-endothelial cell interaction and a reduction in the
expression of MHC II [29]. Previous investigations have noted
the role of statins in the maintenance of microvascular integrity
with restoration of the normal endothelium functioning, and the
inhibition of cell adhesion molecules [30–32]. Thus statins may
have a critical role in the early course of candidemia. Moreover,
statins have demonstrated a direct antifungal effect: the
inhibition of HMG-CoA reductase affects the synthesis of
Table 3. Treatments and clinical outcomes of patients by
statin groups.
 
Statin users (n=44)
No. (%)
Statin non-users
(n=282) No. (%) p-value
Appropriate empirical
antifungal treatment 34 (77.3) 203 (71.9) .464
Antifungal drug selected   .864
Fluconazole 21 (61.7) 117 (57.6)  
Itraconazole 0 (0) 1 (0.5)  
Voriconazole 1 (2.9) 7 (3.4)  
Anidulafungin 4 (11) 22 (10.8)  
Caspofungin 5 (15) 18 (8.8)  
Micafungin 0 (0) 10 (4.9)  
Amphotericin B
deoxycholate 3 (8.8) 20 (9.8)  
Liposomal Amphotericin B 0 (0) 8 (3.9)  
Catheter removal 33 (75) 157 (55.7) .138
Outcomes    
ICU admission 13 (29.5) 88 (31.2) .734
Mechanical ventilation 12 (27.3) 85 (30.1) .596
Instability (at 48h) 15 (34.1) 103 (36.5) .840
Persistent candidemia 5 (11.4) 41 (14.5) .645
Septic metastases 2 (4.5) 13 (4.6) .529
Early case-fatality rate (5d) 2 (4.5) 48 (17) .031
Fourteen days case-fatality
rate (14d) 12 (27) 83 (29) .77
Overall case-fatality rate
(30d) 18 (40.1) 124 (44) .663
doi: 10.1371/journal.pone.0077317.t003
Table 4. Independent factors associated with early case-
fatality rate: multivariate analysis.
Characteristic
Adjusted odds
ratio (AOR)
95% confidence
interval p-value
Age 0.98 0.95-1.005 .104
Sex 1.50 0.63-3.60 .360
Charlson Comorbidity
Index 1.09 0.93-1.27 .307
APACHE II score 1.08 1.03-1.14 .002
Aproppiate empirical
antifungal therapy 0.11 0.04-0.26 <.001
PS 260 1.06-63525 .048
Statin therapy 0.17 0.03–0.93 .041
doi: 10.1371/journal.pone.0077317.t004
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ergosterol, which strongly inhibits the growth of Candida
species. Statins can also cause deletions in the mitochondrial
genome of yeasts, hampering fungal growth [17]. Furthermore,
synergy between statins and fluconazole has been reported,
although not at clinically achievable concentrations [33].
Our study did not shown significant differences in overall
case fatality rate between statins users and non-statins users.
It should be noted, however, that host factors are the most
important factors related with late death in patients with
infection [34–36]. Poor prognosis within the first 30-days of
candidemia is a marker of the fragile status of patients with
candidemia. Therefore, it seems reasonable that a potential
immunomodulatory treatment have not effect in late deaths.
Some researchers have suggested that the beneficial effects
of statins observed in infectious diseases may actually reflect a
healthy user bias. If this was true, this “healthy user behaviour”
would result in apparent benefit for all classes of cardiovascular
drugs [7,13]. However, none of the concomitant cardiovascular
drugs (aspirin, beta-blockers and ACE inhibitors) were
independently associated with mortality in the present study.
Our study has some limitations that should be noted. Firstly,
it was retrospective and ha a small sample size of patients
receiving statins. Secondly, most patients received empirical
treatment with fluconazole. This practice may not necessarily
reflect antifungal empirical choices at this time, after ESCMID
recommendations for equinocandins use [37,38]. Thirdly, it did
not specifically account for types of statins. Fourth, we also
understand that the gut tolerance needed for statin
administration could select a subgroup of patients in better
conditions, even in the absence of differences in the APACHE
II score between groups. Finally, the ideal timing for initiating
statins with respect to the onset of sepsis is still unknown. Our
patients were on chronic treatment with statins at onset of
candidemia. The role of statins administered de novo in the
context of a Candida sepsis should be analyzed in further
studies.
In conclusion, the results of this multicenter study with a
large cohort of hospitalized patients showed that prior statins
use may improve the early case fatality rate in patients with
candidemia. However, overall mortality was not different
between patients receiving statins and those without this drug.
This early beneficial effect of statins deserves to be evaluated
in randomized trials.
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